Jason Harris, Ph.D.

Dr. Harris is Vice President, Research at Autobahn Therapeutics

Jason brings more than 15 years of small molecule drug discovery and development experience to the company having led efforts ranging from hit generation through solid oral dosage development.  Prior to Autobahn, Dr. Harris was head of chemistry and CMC at Ventyx Biosciences, focused on developing therapies to modulate inflammation and innate immunity. There, he was co-inventor of several clinical candidates, including VTX-958 and VTX-2735, and was responsible for the PR&D of VTX-002 through Phase 2 formulation development.  He also served as a senior member of the scientific teams at Escalier Biosciences, Ignyta, Global Blood Therapeutics, and Exelixis. Dr. Harris is a co-inventor/author on more than 60 patents/applications and scientific papers, and contributor to projects that have delivered 9 clinical candidates, including one FDA approved drug (Oxbryta®, GBT).  He holds an undergraduate degree in chemistry from Stony Brook University and a Ph.D. in organic chemistry from University of California, Irvine.